Literature DB >> 26269256

Cartilage oligomeric matrix protein: a new promising biomarker of liver fibrosis in chronic hepatitis C.

Kristofer Andréasson1,2, Roger Hesselstrand1,2, Tore Saxne1,2, Anna Holmberg3,4, Hans Norrgren3,4, Göran Jönsson3,4.   

Abstract

Cartilage oligomeric matrix protein (COMP) is a biomarker of fibrosis in lung and skin. In this exploratory study we investigated the biomarker potential of COMP in chronic hepatitis C (CHC). We included consecutive patients with CHC admitted to the Department of Infectious Diseases, Lund University Hospital. COMP was analysed in serum using ELISA. The correlations between COMP and liver fibrosis, determined by transient elastography (TE) (n = 47) and liver biopsy (n = 28) were assessed. We also studied COMP prospectively in relation to antiviral treatment (n = 10). COMP correlated with the degree of liver fibrosis as assessed by TE (r = 0.71, p < 0.001) and liver biopsy (rs = 0.65, p < 0.001). After successful treatment of CHC, COMP decreased from 18 to 13 U/l (p = 0.011). We suggest that COMP is associated with the stage of liver fibrosis in CHC. The biomarker potential of COMP in CHC warrants further investigation.

Entities:  

Keywords:  COMP; biomarker; chronic hepatitis C; liver fibrosis; transient elastography

Mesh:

Substances:

Year:  2015        PMID: 26269256     DOI: 10.3109/23744235.2015.1075659

Source DB:  PubMed          Journal:  Infect Dis (Lond)        ISSN: 2374-4243


  3 in total

Review 1.  Novel therapeutic interventions for pseudoachondroplasia.

Authors:  Karen L Posey; Jacqueline T Hecht
Journal:  Bone       Date:  2017-03-21       Impact factor: 4.398

2.  Cartilage oligomeric matrix protein participates in the pathogenesis of liver fibrosis.

Authors:  Fernando Magdaleno; Elena Arriazu; Marina Ruiz de Galarreta; Yu Chen; Xiaodong Ge; Laura Conde de la Rosa; Natalia Nieto
Journal:  J Hepatol       Date:  2016-06-15       Impact factor: 25.083

3.  Serum Glycoproteome Profiles for Distinguishing Intestinal Fibrosis from Inflammation in Crohn's Disease.

Authors:  Ryan W Stidham; Jing Wu; Jiaqi Shi; David M Lubman; Peter D R Higgins
Journal:  PLoS One       Date:  2017-01-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.